» Articles » PMID: 28656534

Relationship Between Subjective and Actigraphy-measured Sleep in 237 Patients with Metastatic Colorectal Cancer

Overview
Journal Qual Life Res
Date 2017 Jun 29
PMID 28656534
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Patients with cancers frequently experience sleep and circadian dysfunction. To date, only a few studies have used both a questionnaire and actigraphy for concomitant evaluation of sleep and circadian function in patients with cancer. We sought to evaluate objective sleep and circadian parameters in metastatic colon cancer (MCC) patients and their associations with symptoms and quality of life (QOL).

Methods: Patients reported subjective sleep problems on the EORTC QLQ-C30. Sleep and circadian parameters were calculated using a wrist-actigraph that patients wore for 72 h.

Results: 237 Patients with MCC (mean age: 60.4 years; range: 20.7-77.6; Male/Female ratio: 1.66) participated in this cross-sectional study. Subjective sleep problems were reported by 63.4% of patients (S+). No differences in any sleep parameters (sleep efficiency, sleep latency, total sleep time, total time in bed, wake after sleep onset, activity bathyphase) were observed between S+ and S- patients. However, S+ patients displayed a significantly worse circadian function than S- patients (96.4 vs 98.1%; p = 0.005). The presence of poor subjective sleep and objective circadian dysfunction negatively affected symptoms and QOL domains (p = 0.038).

Conclusions: Subjective report of sleep problems was not associated with worse objectively measured sleep parameters in patients with MCC although it was associated with disrupted circadian rest-activity rhythm and poorer QOL. These findings coincide with prior research in cancer patients in that an inconsistent relationship exists between subjective and objective sleep measurements on some sleep domains. This study supports the value of coupled evaluation of self-reported and objective measures of sleep and circadian function in cancer patients.

Citing Articles

Comparison of subjectively and objectively measured sleep-wake patterns among patients with primary brain tumors.

Kim Y, Kenyon J, Kim J, Willis K, Lanoye A, Loughan A Neurooncol Pract. 2024; 11(6):779-789.

PMID: 39554789 PMC: 11567742. DOI: 10.1093/nop/npae062.


Sleep disturbance in adults with untreated primary brain tumors: prevalence and impact on quality of life.

Lin P, Chen P, Wei K, Lin J, Lin M, Wang H Sleep Biol Rhythms. 2024; 21(2):201-209.

PMID: 38469283 PMC: 10900047. DOI: 10.1007/s41105-022-00436-y.


Circadian rhythm disorders in patients with advanced cancer: a scoping review.

Gouldthorpe C, Power J, Davies A Front Oncol. 2023; 13:1240284.

PMID: 37829342 PMC: 10565850. DOI: 10.3389/fonc.2023.1240284.


Circadian, hormonal, and sleep rhythms: effects on cancer progression implications for treatment.

Jagielo A, Benedict C, Spiegel D Front Oncol. 2023; 13:1269378.

PMID: 37746277 PMC: 10514358. DOI: 10.3389/fonc.2023.1269378.


Prognostication in Advanced Cancer by Combining Actigraphy-Derived Rest-Activity and Sleep Parameters with Routine Clinical Data: An Exploratory Machine Learning Study.

Patel S, Davies A, Laing E, Wu H, Mendis J, Dijk D Cancers (Basel). 2023; 15(2).

PMID: 36672452 PMC: 9856985. DOI: 10.3390/cancers15020503.


References
1.
Di Maio M, Basch E, Bryce J, Perrone F . Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol. 2016; 13(5):319-25. DOI: 10.1038/nrclinonc.2015.222. View

2.
Littner M, Kushida C, Anderson W, Bailey D, Berry R, Davila D . Practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: an update for 2002. Sleep. 2003; 26(3):337-41. DOI: 10.1093/sleep/26.3.337. View

3.
Reppert S, Weaver D . Coordination of circadian timing in mammals. Nature. 2002; 418(6901):935-41. DOI: 10.1038/nature00965. View

4.
de Souza L, Benedito-Silva A, Pires M, Poyares D, Tufik S, Calil H . Further validation of actigraphy for sleep studies. Sleep. 2003; 26(1):81-5. DOI: 10.1093/sleep/26.1.81. View

5.
Kyte D, Reeve B, Efficace F, Haywood K, Mercieca-Bebber R, King M . International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. Qual Life Res. 2015; 25(2):359-362. DOI: 10.1007/s11136-015-1099-z. View